Ustekinumab

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4517 publications

Current management of Behçet syndrome.

Current management of Behçet syndrome.

Journal: Current opinion in rheumatology

Published: October 27, 2026

Correction: Pharmacokinetics, Safety, and Immunogenicity of DMB-3115, a Ustekinumab Biosimilar for Immune-Mediated Diseases, in Healthy Japanese Male Participants: A Randomized, Double-Blind, Single-Dose Study.

Correction: Pharmacokinetics, Safety, and Immunogenicity of DMB-3115, a Ustekinumab Biosimilar for Immune-Mediated Diseases, in Healthy Japanese Male Participants: A Randomized, Double-Blind, Single-Dose Study.

Journal: Advances in therapy

Published: October 27, 2026

Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization.

Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization.

Journal: Revista espanola de enfermedades digestivas

Published: October 26, 2026

Analysis of the disease remission outcomes and the associated factors of deep remission in patients with Crohn disease receiving ustekinumab therapy

Analysis of the disease remission outcomes and the associated factors of deep remission in patients with Crohn disease receiving ustekinumab therapy

Journal: Zhonghua yi xue za zhi

Published: October 25, 2026

Noninfectious skin lesions in Crohn's disease patients treated with ustekinumab: a multicenter observational retrospective GETAID study.

Noninfectious skin lesions in Crohn's disease patients treated with ustekinumab: a multicenter observational retrospective GETAID study.

Journal: Journal of Crohn's & colitis

Published: October 24, 2026

Comparative Effectiveness of Vedolizumab and Ustekinumab in Biologic-Experienced Ulcerative Colitis: A Real-World Multicenter Study from the Güntürk Group.

Comparative Effectiveness of Vedolizumab and Ustekinumab in Biologic-Experienced Ulcerative Colitis: A Real-World Multicenter Study from the Güntürk Group.

Journal: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

Published: October 23, 2026

Comparative drug survival of biologic classes in psoriasis: a Japanese single-centre cohort study.

Comparative drug survival of biologic classes in psoriasis: a Japanese single-centre cohort study.

Journal: European journal of dermatology : EJD

Published: October 12, 2026

Effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors and factors associated with response in psoriatic arthritis with axial involvement: the APxis-IL12-23 study.

Effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors and factors associated with response in psoriatic arthritis with axial involvement: the APxis-IL12-23 study.

Journal: Scandinavian journal of rheumatology

Published: October 09, 2026

A Giant Intra-Abdominal Plasmablastic Neoplasm Favoring Lymphoma Mimicking an Exacerbation of Severe Fistulizing Crohn's Disease: A Case Report.

A Giant Intra-Abdominal Plasmablastic Neoplasm Favoring Lymphoma Mimicking an Exacerbation of Severe Fistulizing Crohn's Disease: A Case Report.

Journal: The American journal of case reports

Published: October 09, 2026

Hospitalized Infection Risk and Organ-specific Infection Patterns Across Advanced Therapies in Ulcerative Colitis: A Japanese Claims Analysis.

Hospitalized Infection Risk and Organ-specific Infection Patterns Across Advanced Therapies in Ulcerative Colitis: A Japanese Claims Analysis.

Journal: Internal medicine (Tokyo, Japan)

Published: October 07, 2026

Real-world effectiveness and safety of risankizumab induction and maintenance therapy in pediatric patients with Crohn's disease: a multicenter retrospective analysis.

Real-world effectiveness and safety of risankizumab induction and maintenance therapy in pediatric patients with Crohn's disease: a multicenter retrospective analysis.

Journal: Journal of Crohn's & colitis

Published: September 30, 2026

Infliximab-Associated Paradoxical Psoriasiform Reaction in Pediatric Ulcerative Colitis: Resolution with Ustekinumab.

Infliximab-Associated Paradoxical Psoriasiform Reaction in Pediatric Ulcerative Colitis: Resolution with Ustekinumab.

Journal: American journal of therapeutics

Published: September 29, 2026

Showing 1-12 of 4,517

Last Updated: 11/08/2026